Ionis Entered into an Agreement with Roche for Two Novel RNA-Targeted Programs for Alzheimer's and Huntington's disease
Shots:
- Ionis will receive $60M up front and is eligible to receive development, regulatory, and commercial milestones along with royalties
- Roche gets an exclusive right globally to develop, manufacture and commercialize the investigational therapies discovered by Ionis if approved. Ionis will be responsible for advancing the two programs through pre-clinical studies
- The companies will combine Ionis' expertise in discovering medicines that target the root cause of CNS diseases and Roche's global experience in developing and commercializing therapies for nervous system disorders to develop and deliver innovative treatments to patients
Ref: PR Newswire | Image: Ionis
Related News:- Ionis Reports P-III Study (Balance) Results of Olezarsen for Familial Chylomicronemia Syndrome
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
